Ryan A. Lafferty

621 total citations
30 papers, 491 citations indexed

About

Ryan A. Lafferty is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Ryan A. Lafferty has authored 30 papers receiving a total of 491 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Endocrinology, Diabetes and Metabolism, 17 papers in Surgery and 12 papers in Molecular Biology. Recurrent topics in Ryan A. Lafferty's work include Pancreatic function and diabetes (17 papers), Diabetes Treatment and Management (14 papers) and Neuropeptides and Animal Physiology (12 papers). Ryan A. Lafferty is often cited by papers focused on Pancreatic function and diabetes (17 papers), Diabetes Treatment and Management (14 papers) and Neuropeptides and Animal Physiology (12 papers). Ryan A. Lafferty collaborates with scholars based in United Kingdom, Ireland and Sweden. Ryan A. Lafferty's co-authors include Peter R. Flatt, Nigel Irwin, Brendan Gilmore, Julianne Megaw, Thomas P. Thompson, Neil Tanday, Finbarr O’Harte, Victor A. Gault, Pádraigín A. Harnedy‐Rothwell and Richard J. Fitzgerald and has published in prestigious journals such as PLoS ONE, Chemosphere and Biochemical Pharmacology.

In The Last Decade

Ryan A. Lafferty

30 papers receiving 489 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryan A. Lafferty United Kingdom 13 217 186 160 123 103 30 491
Michaël Chevrot France 7 49 0.2× 132 0.7× 65 0.4× 31 0.3× 94 0.9× 9 498
Molly Moloney United States 9 196 0.9× 186 1.0× 145 0.9× 71 0.6× 64 0.6× 9 486
Céline Martin France 8 44 0.2× 141 0.8× 64 0.4× 30 0.2× 75 0.7× 13 492
Martin Roumain Belgium 12 78 0.4× 329 1.8× 67 0.4× 10 0.1× 230 2.2× 23 611
J. R. PFISTER United States 10 84 0.4× 204 1.1× 23 0.1× 93 0.8× 99 1.0× 15 468
Abdoulaye Diané Canada 13 52 0.2× 87 0.5× 61 0.4× 17 0.1× 96 0.9× 41 383
Hiroaki Tsuzuki Japan 5 94 0.4× 377 2.0× 93 0.6× 30 0.2× 345 3.3× 8 611
Jesús Chávez‐Reyes Mexico 10 44 0.2× 107 0.6× 48 0.3× 53 0.4× 51 0.5× 20 351
Xuhong Lin China 12 27 0.1× 159 0.9× 81 0.5× 19 0.2× 49 0.5× 29 442
Katarina Mitić Serbia 14 21 0.1× 116 0.6× 37 0.2× 146 1.2× 67 0.7× 49 488

Countries citing papers authored by Ryan A. Lafferty

Since Specialization
Citations

This map shows the geographic impact of Ryan A. Lafferty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan A. Lafferty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan A. Lafferty more than expected).

Fields of papers citing papers by Ryan A. Lafferty

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan A. Lafferty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan A. Lafferty. The network helps show where Ryan A. Lafferty may publish in the future.

Co-authorship network of co-authors of Ryan A. Lafferty

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan A. Lafferty. A scholar is included among the top collaborators of Ryan A. Lafferty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan A. Lafferty. Ryan A. Lafferty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lafferty, Ryan A., Peter R. Flatt, Victor A. Gault, & Nigel Irwin. (2024). Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?. Journal of Endocrinology. 262(2). 3 indexed citations
2.
3.
Lafferty, Ryan A., Peter R. Flatt, & Nigel Irwin. (2023). GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy. Expert Opinion on Pharmacotherapy. 24(5). 587–597. 36 indexed citations
4.
Lafferty, Ryan A., Neil Tanday, Vaibhav Dubey, et al.. (2023). The glucagon receptor antagonist desHis1Pro4Glu9-glucagon(Lys12PAL) alters alpha-cell turnover and lineage in mice, but does not cause alpha-cell hyperplasia. Molecular and Cellular Endocrinology. 570. 111932–111932. 2 indexed citations
5.
Lafferty, Ryan A., Neil Tanday, Vaibhav Dubey, et al.. (2023). The Glucagon Receptor Antagonist desHis1Pro4Glu9-Glucagon(Lys12PAL) Alters Alpha-Cell Turnover and Lineage in Mice, But Does Not Cause Alpha-Cell Hyperplasia. SSRN Electronic Journal. 1 indexed citations
6.
Lafferty, Ryan A., et al.. (2022). Sustained glucagon receptor antagonism in insulin-deficient high-fat-fed mice. Journal of Endocrinology. 255(2). 91–101. 5 indexed citations
7.
Tanday, Neil, Ryan A. Lafferty, Peter R. Flatt, & Nigel Irwin. (2022). Beneficial metabolic effects of recurrent periods of beta‐cell rest and stimulation using stable neuropeptide Y1 and glucagon‐like peptide‐1 receptor agonists. Diabetes Obesity and Metabolism. 24(12). 2353–2363. 11 indexed citations
8.
Lafferty, Ryan A., et al.. (2022). Effects of artemether on pancreatic islet morphology, islet cell turnover and α-cell transdifferentiation in insulin-deficient Glu CreERT2;ROSA26-eYFP diabetic mice. Journal of Pharmacy and Pharmacology. 74(12). 1758–1764. 5 indexed citations
9.
Lafferty, Ryan A., Peter R. Flatt, & Nigel Irwin. (2022). Is polypharmacy the future for pharmacological management of obesity?. Current Opinion in Endocrine and Metabolic Research. 23. 100322–100322. 8 indexed citations
10.
11.
Lafferty, Ryan A., et al.. (2022). Antidiabetic actions of GPR55 agonist Abn-CBD and sitagliptin in obese-diabetic high fat fed mice. Biochemical Pharmacology. 208. 115398–115398. 7 indexed citations
12.
13.
Harnedy‐Rothwell, Pádraigín A., Ryan A. Lafferty, Vadivel Parthsarathy, et al.. (2021). Macroalgal protein hydrolysates from Palmaria palmata influence the ‘incretin effect’ in vitro via DPP-4 inhibition and upregulation of insulin, GLP-1 and GIP secretion. European Journal of Nutrition. 60(8). 4439–4452. 21 indexed citations
14.
Tanday, Neil, Andrew English, Ryan A. Lafferty, Peter R. Flatt, & Nigel Irwin. (2021). Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes. Frontiers in Endocrinology. 12. 674704–674704. 15 indexed citations
15.
Lafferty, Ryan A., Neil Tanday, Peter R. Flatt, & Nigel Irwin. (2020). Generation and characterisation of C-terminally stabilised PYY molecules with potential in vivo NPYR2 activity. Metabolism. 111. 154339–154339. 8 indexed citations
16.
Lafferty, Ryan A., Peter R. Flatt, & Nigel Irwin. (2020). Established and emerging roles peptide YY (PYY) and exploitation in obesity–diabetes. Current Opinion in Endocrinology Diabetes and Obesity. 28(2). 253–261. 32 indexed citations
17.
Lafferty, Ryan A., Neil Tanday, Pradeep Bompada, et al.. (2019). Peptide YY (1–36) peptides from phylogenetically ancient fish targeting mammalian neuropeptide Y1 receptors demonstrate potent effects on pancreatic β‐cell function, growth and survival. Diabetes Obesity and Metabolism. 22(3). 404–416. 22 indexed citations
18.
Lafferty, Ryan A., Peter R. Flatt, & Nigel Irwin. (2018). C-terminal degradation of PYY peptides in plasma abolishes effects on satiety and beta-cell function. Biochemical Pharmacology. 158. 95–102. 21 indexed citations
19.
Lafferty, Ryan A., Peter R. Flatt, & Nigel Irwin. (2018). Emerging therapeutic potential for peptide YY for obesity-diabetes. Peptides. 100. 269–274. 60 indexed citations
20.
Megaw, Julianne, Thomas P. Thompson, Ryan A. Lafferty, & Brendan Gilmore. (2015). Galleria mellonella as a novel in vivo model for assessment of the toxicity of 1-alkyl-3-methylimidazolium chloride ionic liquids. Chemosphere. 139. 197–201. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michaël Chevrot Breakdown of academic impact, for papers by Molly Moloney Breakdown of academic impact, for papers by Céline Martin Breakdown of academic impact, for papers by Martin Roumain Breakdown of academic impact, for papers by J. R. PFISTER Breakdown of academic impact, for papers by Abdoulaye Diané Breakdown of academic impact, for papers by Hiroaki Tsuzuki Breakdown of academic impact, for papers by Jesús Chávez‐Reyes Breakdown of academic impact, for papers by Xuhong Lin Breakdown of academic impact, for papers by Katarina Mitić
Rankless by CCL
2026